Zaree Babakhanian, MD
Gastroenterology · Glendale
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 18 years
- Chicago College of Medicine and Surgery, 2008
Offices
1 location · Genesis Healthcare Partners PC · 232 clinicians in this group
Looking this up.
Hospitals listed: Huntington Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Babakhanian’s office at (818) 790-5194 to ask if they take your plan before you enroll.
California Medical Board record
Licence A109953 · Current
Licensed to practise in California · since 2009 · expires 2027-04-30 · Rosalind Franklin University, the Chicago Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Huntington HospitalPasadena, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Cedars Sinai Health System, which runs 4 hospitalsPatients rate it 3 of 5 · 76% would definitely recommend itNo overall ratingNo measure marked better or worse than the national rate
See every measure and the patient survey for Huntington Hospital
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Readmissions: 1 better, 6 the same, 2 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.68 (0 to 1.56) · 2,225 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.9 (0.63 to 1.17) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 149.43 (106.58 to 192.28) · 128 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.8 · 67 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.6 · 112 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 8.8 · 171 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 475 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.7 · 822 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 463 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 5,850 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.36) · 10,123 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.07 to 0.43) · 10,515 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.4 (2.67 to 6.13) · 2,613 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.32 (0 to 2.86) · 1,209 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.77 (1.44 to 4.11) · 2,457 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.71 (1.95 to 13.48) · 1,211 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.08 (0.8 to 7.36) · 1,189 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.85 (0.42 to 3.29) · 825 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.56 (0.03 to 1.09) · 8,956 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 269 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.448 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | No different | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.977 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.423 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.9 · 253 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 18.9 · 846 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 5.2 · 176 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 20.1 · 542 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 9.5 · 864 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.2 · 1,144 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.2 to 8.5) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (6.9 to 15.2) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 260 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.1 · 87 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.4 · 201 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.8 (8.8 to 15.8) · 365 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1) · 786 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,430 patients answered, 23% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
Original Medicare doctor bills
$106,403
Medicare paid this office $106,403 for 472 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 204 | $44,075 | $215 |
| Return visit (30+ min) | 140 | $18,822 | $102 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 141 | $9,266 | $65 |
| New patient visit (45+ min) | 69 | $9,137 | $132 |
| Short return visit (20+ min) | 75 | $7,090 | $73 |
See all 13 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 204 | $44,075 | $215 |
| Return visit (30+ min) | 140 | $18,822 | $102 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 141 | $9,266 | $65 |
| New patient visit (45+ min) | 69 | $9,137 | $132 |
| Short return visit (20+ min) | 75 | $7,090 | $73 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 25 | $4,292 | $172 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 12 | $2,125 | $177 |
| Biopsy of large bowel using a flexible endoscope | 19 | $1,823 | $96 |
| New patient visit (30+ min) | 17 | $1,629 | $96 |
| Diagnostic exam of large bowel using a flexible endoscope | 11 | $1,455 | $132 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 12 | $921 | $77 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 165 | $623 | $4 |
| Injection beneath lining of large bowel using a flexible endoscope | 17 | $225 | $13 |
Procedures Medicare counted
| Colonoscopy | 113 | More than 82% of doctors who do this |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 121 | More than 81% of doctors who do this |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 97 | 78 | 100 | 175 | 172 | 205 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 79 | 70 | 94 | 134 | 136 | 143 |
| Biopsy of large bowel using a flexible endoscope | 45 | 23 | 47 | 41 | 51 | 19 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 23 | 16 | 15 | 15 | 14 | 12 |
| Injection beneath lining of large bowel using a flexible endoscope | – | – | 11 | 13 | 15 | 17 |
| Diagnostic exam of large bowel using a flexible endoscope | – | – | – | – | 13 | 11 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
472 Original Medicare patients in 2024. Average age 72 · Under 65 8% · 85 and older 6% · Women 58% · Also on Medicaid 60% · Health risk score 1.30. At or below the middle of the specialty; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 75% · Coronary heart disease 46% · Diabetes 45% · Depression 40% · COPD 21% · Heart failure 20% · Chronic kidney disease 20% · Cancer 14% · Dementia 14% · Atrial fibrillation 10% · Stroke 8%.
The office billed $678,920, Medicare allowed $134,691 and paid $106,403; for 1,016 services of 30 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 472 | 1,016 | 72 | 1.30 | $678,920 | $106,403 |
| 2023 | 492 | 1,093 | 73 | 1.42 | $667,215 | $105,786 |
| 2022 | 547 | 1,342 | 73 | 1.32 | $575,206 | $126,763 |
| 2021 | 372 | 980 | 73 | 1.54 | $346,451 | $101,268 |
| 2020 | 318 | 811 | 73 | 1.81 | $315,302 | $91,572 |
| 2019 | 379 | 982 | 74 | 1.79 | $256,098 | $98,632 |
| 2018 | 350 | 994 | 73 | 2.03 | $240,953 | $92,755 |
| 2017 | 330 | 876 | 73 | 2.15 | $223,037 | $84,939 |
| 2016 | 231 | 565 | 75 | 2.14 | $173,589 | $65,511 |
| 2014 | 11 | 31 | 79 | 1.87 | $10,720 | $3,822 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 15 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 171 | $36,824 | $214 |
| Return visit (30+ min) | 121 | $15,416 | $103 |
| New patient visit (45+ min) | 77 | $9,455 | $123 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 134 | $8,725 | $64 |
| Short return visit (20+ min) | 90 | $7,197 | $66 |
| Biopsy of large bowel using a flexible endoscope | 51 | $4,531 | $89 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 16 | $2,736 | $171 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 15 | $2,732 | $182 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $2,649 | $132 |
| New patient visit (30+ min) | 29 | $2,269 | $78 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $2,111 | $92 |
| Diagnostic exam of large bowel using a flexible endoscope | 13 | $1,794 | $138 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 14 | $1,229 | $88 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 194 | $768 | $4 |
| Injection beneath lining of large bowel using a flexible endoscope | 14 | $204 | $14 |
2022: 15 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 175 | $37,191 | $213 |
| New patient visit (45+ min) | 146 | $18,661 | $128 |
| Return visit (30+ min) | 102 | $13,612 | $102 |
| New patient visit (30+ min) | 166 | $13,338 | $80 |
| Short return visit (20+ min) | 131 | $10,581 | $63 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 134 | $9,191 | $69 |
| Biopsy of large bowel using a flexible endoscope | 41 | $2,907 | $71 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,503 | $167 |
| Long return visit (40+ min) | 15 | $2,180 | $145 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 12 | $2,169 | $181 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $1,891 | $86 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $1,257 | $60 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 15 | $1,155 | $77 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 189 | $800 | $4 |
| Injection beneath lining of large bowel using a flexible endoscope | 13 | $176 | $14 |
2021: 16 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 98 | $22,024 | $220 |
| New patient visit (45+ min) | 121 | $14,734 | $122 |
| Return visit (30+ min) | 79 | $11,726 | $107 |
| Short return visit (20+ min) | 93 | $8,922 | $70 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 90 | $7,554 | $80 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 38 | $7,024 | $171 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $4,595 | $88 |
| Biopsy of large bowel using a flexible endoscope | 46 | $4,014 | $85 |
| New patient visit (60+ min) | 21 | $3,767 | $179 |
| Long return visit (40+ min) | 15 | $2,237 | $149 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 22 | $1,967 | $61 |
| New patient visit (30+ min) | 23 | $1,886 | $82 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 13 | $1,281 | $85 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 87 | $368 | $4 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 12 | $186 | $16 |
| Injection beneath lining of large bowel using a flexible endoscope | 11 | $149 | $14 |
2020: 12 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 77 | $17,626 | $226 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 69 | $13,372 | $176 |
| New patient visit (45+ min) | 83 | $11,508 | $139 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 51 | $6,281 | $63 |
| Short return visit (20+ min) | 72 | $5,641 | $57 |
| Return visit (30+ min) | 50 | $4,957 | $92 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 69 | $4,949 | $71 |
| Removal of stone or debris from bile or pancreatic duct using a flexible endoscope | 14 | $2,807 | $201 |
| New patient visit (30+ min) | 28 | $2,448 | $87 |
| Biopsy of large bowel using a flexible endoscope | 22 | $1,728 | $75 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 14 | $1,580 | $99 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 45 | $183 | $4 |
2019: 12 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 97 | $21,419 | $221 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 68 | $12,947 | $173 |
| Return visit (30+ min) | 80 | $8,602 | $86 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 57 | $7,760 | $62 |
| Short return visit (20+ min) | 95 | $7,413 | $61 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 77 | $5,917 | $75 |
| New patient visit (45+ min) | 50 | $5,322 | $106 |
| Biopsy of large bowel using a flexible endoscope | 45 | $5,103 | $113 |
| New patient visit (30+ min) | 28 | $2,512 | $90 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 12 | $2,440 | $203 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 23 | $2,165 | $94 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 110 | $379 | $3 |
2018: 13 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 102 | $22,945 | $219 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 69 | $12,935 | $172 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 64 | $8,422 | $62 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 77 | $6,242 | $78 |
| New patient visit (45+ min) | 46 | $6,083 | $132 |
| Short return visit (20+ min) | 74 | $5,498 | $55 |
| Return visit (30+ min) | 50 | $5,029 | $87 |
| Biopsy of large bowel using a flexible endoscope | 25 | $3,044 | $117 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 24 | $2,548 | $102 |
| New patient visit (30+ min) | 27 | $2,113 | $78 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,393 | $116 |
| Use of a drug to induce depression of consciousness by physician performing a procedure, each additional 15 minutes | 86 | $710 | $8 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 108 | $432 | $4 |
2017: 15 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 65 | $14,538 | $224 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 83 | $14,197 | $163 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 71 | $8,357 | $59 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 69 | $6,701 | $91 |
| New patient visit (45+ min) | 46 | $5,559 | $121 |
| Short return visit (20+ min) | 63 | $4,756 | $57 |
| Return visit (30+ min) | 42 | $4,320 | $85 |
| Biopsy of large bowel using a flexible endoscope | 39 | $3,375 | $87 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 21 | $2,439 | $116 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 12 | $2,341 | $195 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 11 | $2,132 | $194 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 22 | $2,117 | $96 |
| New patient visit (30+ min) | 19 | $1,509 | $79 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 79 | $358 | $4 |
| Use of a drug to induce depression of consciousness by physician performing a procedure, each additional 15 minutes | 23 | $222 | $10 |
2016: 11 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 49 | $11,708 | $230 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 57 | $10,301 | $172 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 55 | $6,412 | $60 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 51 | $4,455 | $84 |
| New patient visit (45+ min) | 31 | $4,055 | $131 |
| Biopsy of large bowel using a flexible endoscope | 34 | $3,533 | $98 |
| Short return visit (20+ min) | 45 | $3,287 | $63 |
| Return visit (30+ min) | 27 | $3,159 | $93 |
| New patient visit (30+ min) | 25 | $2,225 | $89 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 15 | $1,583 | $106 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,275 | $106 |
Drugs they prescribed that Part D paid
$558,292
Pharmacies billed $558,292 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
1,115 generic and 272 brand-name prescriptions · $558,292 in drug cost · 49 antibiotic prescriptions to 19 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Stelara | 12 | $324,304 | $27,025 |
| Creon | 126 | $112,722 | $895 |
| Linzess | 81 | $44,697 | $552 |
| Omeprazole-Sodium Bicarbonate | 19 | $23,241 | $1,223 |
| Zenpep | 16 | $18,304 | $1,144 |
See all 17 drugs
| Stelara | 12 | $324,304 | $27,025 |
| Creon | 126 | $112,722 | $895 |
| Linzess | 81 | $44,697 | $552 |
| Omeprazole-Sodium Bicarbonate | 19 | $23,241 | $1,223 |
| Zenpep | 16 | $18,304 | $1,144 |
| Dexlansoprazole Dr | 23 | $4,421 | $192 |
| Omeprazole | 351 | $2,704 | $8 |
| Pantoprazole | 171 | $1,706 | $10 |
| Mesalamine Er | 17 | $1,630 | $96 |
| Budesonide Dr | 25 | $1,426 | $57 |
| Famotidine | 230 | $1,082 | $5 |
| Sucralfate | 59 | $696 | $12 |
| Dicyclomine | 47 | $448 | $10 |
| Lansoprazole | 33 | $381 | $12 |
| Amitriptyline | 32 | $273 | $9 |
| Metronidazole | 22 | $174 | $8 |
| Esomeprazole Magnesium | 16 | $90 | $6 |
Year by year
| 2024 | 1,387 | 258 | None | 20% | $558,292 |
| 2023 | 1,188 | 205 | 0% (0) | 18% | $544,217 |
| 2022 | 987 | 201 | 0% (0) | 22% | $506,732 |
| 2021 | 771 | 179 | None | 18% | $147,259 |
| 2020 | 506 | 143 | 0% (0) | 17% | $88,801 |
| 2019 | 619 | 152 | 0% (0) | 27% | $203,533 |
| 2018 | 693 | 164 | None | 19% | $130,698 |
| 2017 | 652 | 124 | None | 17% | $156,925 |
| 2016 | 551 | 110 | None | 26% | $96,524 |
| 2015 | 319 | 83 | None | 26% | $38,381 |
| 2014 | 43 | 22 | 0% (0) | None | $1,498 |
| 2013 | 68 | 27 | None | 41% | $18,259 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 17 drugs
| Stelara | 13 | $334,743 | $25,749 |
| Creon | 76 | $77,168 | $1,015 |
| Linzess | 67 | $43,266 | $646 |
| Dexlansoprazole Dr | 47 | $12,889 | $274 |
| Mesalamine | 14 | $11,571 | $827 |
| Omeprazole | 348 | $5,944 | $17 |
| Mesalamine Er | 16 | $5,782 | $361 |
| Budesonide Dr | 24 | $3,850 | $160 |
| Nexium | 12 | $3,641 | $303 |
| Famotidine | 216 | $3,477 | $16 |
| Pantoprazole | 150 | $2,660 | $18 |
| Sucralfate | 41 | $1,764 | $43 |
| Lansoprazole | 28 | $1,308 | $47 |
| Loperamide | 16 | $388 | $24 |
| Dicyclomine | 16 | $264 | $16 |
| Metronidazole | 15 | $161 | $11 |
| Amitriptyline | 15 | $124 | $8 |
2022: 16 drugs
| Humira(Cf) | 13 | $88,342 | $6,796 |
| Creon | 82 | $83,823 | $1,022 |
| Linzess | 53 | $30,223 | $570 |
| Mesalamine | 16 | $16,360 | $1,022 |
| Budesonide Ec | 15 | $13,615 | $908 |
| Dexilant | 29 | $10,977 | $379 |
| Mesalamine Er | 15 | $6,222 | $415 |
| Lansoprazole | 15 | $4,544 | $303 |
| Omeprazole | 341 | $3,995 | $12 |
| Lactulose | 16 | $2,480 | $155 |
| Famotidine | 134 | $1,647 | $12 |
| Pantoprazole | 92 | $1,313 | $14 |
| Sucralfate | 24 | $798 | $33 |
| Budesonide Dr | 12 | $752 | $63 |
| Amitriptyline | 27 | $268 | $10 |
| Dicyclomine | 14 | $239 | $17 |
2021: 16 drugs
| Creon | 40 | $43,394 | $1,085 |
| Mesalamine | 18 | $17,827 | $990 |
| Linzess | 23 | $12,453 | $541 |
| Apriso | 13 | $7,096 | $546 |
| Mesalamine Er | 13 | $5,791 | $445 |
| Omeprazole | 255 | $3,385 | $13 |
| Pantoprazole | 104 | $2,020 | $19 |
| Budesonide Dr | 17 | $2,002 | $118 |
| Lansoprazole | 11 | $1,680 | $153 |
| Famotidine | 79 | $1,499 | $19 |
| Sucralfate | 39 | $1,477 | $38 |
| Ondansetron Odt | 16 | $659 | $41 |
| Clarithromycin | 15 | $477 | $32 |
| Metronidazole | 12 | $142 | $12 |
| Amoxicillin | 13 | $116 | $9 |
| Amitriptyline | 13 | $99 | $8 |
2020: 12 drugs
| Dexilant | 32 | $16,031 | $501 |
| Creon | 14 | $13,643 | $974 |
| Mesalamine | 17 | $13,476 | $793 |
| Linzess | 12 | $10,694 | $891 |
| Omeprazole | 130 | $1,420 | $11 |
| Pantoprazole | 98 | $1,360 | $14 |
| Sucralfate | 20 | $909 | $45 |
| Famotidine | 37 | $609 | $16 |
| Clarithromycin | 11 | $386 | $35 |
| Dicyclomine | 20 | $273 | $14 |
| Prednisone | 15 | $85 | $6 |
| Amoxicillin | 11 | $66 | $6 |
2019: 9 drugs
| Dexilant | 54 | $20,957 | $388 |
| Linzess | 24 | $17,516 | $730 |
| Creon | 17 | $17,408 | $1,024 |
| Apriso | 14 | $8,589 | $614 |
| Pantoprazole | 147 | $1,858 | $13 |
| Omeprazole | 88 | $1,638 | $19 |
| Ranitidine | 64 | $758 | $12 |
| Sucralfate | 22 | $611 | $28 |
| Famotidine | 22 | $318 | $14 |
2018: 12 drugs
| Creon | 19 | $17,840 | $939 |
| Omeprazole-Sodium Bicarbonate | 11 | $13,854 | $1,259 |
| Linzess | 31 | $12,872 | $415 |
| Dexilant | 42 | $12,464 | $297 |
| Apriso | 11 | $5,413 | $492 |
| Balsalazide Disodium | 11 | $2,541 | $231 |
| Pantoprazole | 177 | $2,288 | $13 |
| Omeprazole | 115 | $1,507 | $13 |
| Sucralfate | 43 | $966 | $22 |
| Polyethylene Glycol 3350 | 45 | $847 | $19 |
| Ranitidine | 71 | $642 | $9 |
| Famotidine | 27 | $388 | $14 |
2017: 11 drugs
| Asacol Hd | 12 | $19,586 | $1,632 |
| Lialda | 12 | $12,919 | $1,077 |
| Creon | 14 | $12,066 | $862 |
| Dexilant | 27 | $10,256 | $380 |
| Linzess | 14 | $4,862 | $347 |
| Pantoprazole | 145 | $1,515 | $10 |
| Omeprazole | 107 | $1,359 | $13 |
| Sucralfate | 53 | $1,252 | $24 |
| Ranitidine | 61 | $602 | $10 |
| Famotidine | 26 | $263 | $10 |
| Polyethylene Glycol 3350 | 13 | $251 | $19 |
2016: 11 drugs
| Asacol Hd | 20 | $27,034 | $1,352 |
| Lialda | 12 | $11,540 | $962 |
| Dexilant | 43 | $10,323 | $240 |
| Nexium | 23 | $7,340 | $319 |
| Pantoprazole | 106 | $1,214 | $11 |
| Omeprazole | 85 | $979 | $12 |
| Clarithromycin | 13 | $529 | $41 |
| Ranitidine | 43 | $395 | $9 |
| Famotidine | 17 | $312 | $18 |
| Polyethylene Glycol 3350 | 17 | $199 | $12 |
| Amoxicillin | 11 | $109 | $10 |
2015: 6 drugs
| Nexium | 30 | $9,395 | $313 |
| Dexilant | 28 | $6,608 | $236 |
| Delzicol | 12 | $5,973 | $498 |
| Pantoprazole | 96 | $1,112 | $12 |
| Omeprazole | 52 | $522 | $10 |
| Ranitidine | 17 | $125 | $7 |
Money from drug and device companies
$734 in 2025
| 2025 | 7 | 42 | None | $734 |
| 2024 | 6 | 46 | None | $930 |
| 2023 | 3 | 42 | None | $758 |
| 2022 | 3 | 49 | None | $959 |
| 2021 | 4 | 20 | None | $438 |
| 2020 | 3 | 17 | None | $274 |
| 2019 | 10 | 66 | None | $800 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Rinvoq | $274 | 19 payments
|
| Janssen Biotech | Tremfya | $269 | 14 payments
|
| Lilly USA | Omvoh | $79 | 4 payments
|
| Celltrion USA | Vegzelma | $52 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $27 | 1 payment
|
| Boston Scientific | General - Biliary Devices | $23 | 1 payment
|
See all 42 published payments
| Abbvie | Meals · 2025-12-16 | Skyrizi | $23 |
| Abbvie | Meals · 2025-11-18 | Rinvoq | $3 |
| Abbvie | Meals · 2025-11-18 | Skyrizi | $17 |
| Abbvie | Meals · 2025-11-07 | Skyrizi | $26 |
| Abbvie | Meals · 2025-11-06 | Rinvoq | $15 |
| Abbvie | Meals · 2025-11-06 | Rinvoq | $17 |
| Janssen Biotech | Meals · 2025-10-31 | Tremfya | $25 |
| Abbvie | Meals · 2025-10-27 | Skyrizi | $4 |
| Abbvie | Meals · 2025-10-27 | Rinvoq | $11 |
| Janssen Biotech | Meals · 2025-10-14 | Tremfya | $19 |
| Janssen Biotech | Meals · 2025-10-01 | Tremfya | $21 |
| Abbvie | Meals · 2025-09-09 | Rinvoq | $15 |
| Abbvie | Meals · 2025-08-30 | Rinvoq | $12 |
| Janssen Biotech | Meals · 2025-08-26 | Tremfya | $19 |
| Abbvie | Meals · 2025-08-19 | Rinvoq | $13 |
| Lilly USA | Meals · 2025-08-12 | Omvoh | $21 |
| Abbvie | Meals · 2025-08-09 | Rinvoq | $1 |
| Abbvie | Meals · 2025-08-08 | Rinvoq | $13 |
| Abbvie | Meals · 2025-07-31 | Rinvoq | $18 |
| Janssen Biotech | Meals · 2025-07-29 | Tremfya | $20 |
| Janssen Biotech | Meals · 2025-06-17 | Tremfya | $19 |
| Celltrion USA | Meals · 2025-06-05 | Vegzelma | $15 |
| Abbvie | Meals · 2025-05-31 | Rinvoq | $13 |
| Janssen Biotech | Meals · 2025-05-13 | Tremfya | $17 |
| Janssen Biotech | Meals · 2025-05-09 | Tremfya | $18 |
| Abbvie | Meals · 2025-05-07 | Rinvoq | $17 |
| Lilly USA | Meals · 2025-05-06 | Omvoh | $14 |
| Janssen Pharmaceuticals | Education · 2025-04-16 | None | $10 |
| Janssen Biotech | Meals · 2025-04-16 | Tremfya | $20 |
| Lilly USA | Meals · 2025-04-01 | Omvoh | $21 |
| Janssen Biotech | Meals · 2025-03-25 | Tremfya | $19 |
| Celltrion USA | Meals · 2025-03-19 | Vegzelma | $36 |
| Boston Scientific | Meals · 2025-03-17 | General - Biliary Devices | $23 |
| Abbvie | Meals · 2025-03-17 | Rinvoq | $27 |
| Janssen Biotech | Meals · 2025-03-03 | Tremfya | $18 |
| Lilly USA | Meals · 2025-02-24 | Omvoh | $24 |
| Janssen Biotech | Meals · 2025-02-18 | Tremfya | $19 |
| Abbvie | Meals · 2025-02-06 | Rinvoq | $16 |
| Janssen Biotech | Meals · 2025-02-04 | Tremfya | $18 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-01-27 | Entyvio | $27 |
| Janssen Biotech | Meals · 2025-01-14 | Tremfya | $17 |
| Abbvie | Meals · 2025-01-13 | Rinvoq | $15 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $930
| Abbvie | Rinvoq | $494 | 28 payments
|
| Janssen Biotech | Stelara | $217 | 13 payments
|
| Intuitive Surgical | Da Vinci Surgical System | $110 | 1 payment
|
| Celltrion USA | Vegzelma | $45 | 2 payments
|
| Gilead Sciences | None | $34 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $31 | 1 payment
|
2023: $758
| AbbVie | Rinvoq | $450 | 26 payments
|
| Janssen Biotech | Stelara | $279 | 14 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $29 | 2 payments
|
2022: $959
| Abbvie | Rinvoq | $835 | 42 payments
|
| Janssen Biotech | Stelara | $106 | 6 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $17 | 1 payment
|
2021: $438
| AbbVie | Humira | $321 | 13 payments
|
| Janssen Biotech | Stelara | $92 | 5 payments
|
| Celgene | Zeposia | $14 | 1 payment
|
| Nestle HealthCare Nutrition | Zenpep | $11 | 1 payment
|
2020: $274
| AbbVie | Humira | $129 | 9 payments
|
| Janssen Biotech | Stelara | $126 | 7 payments
|
| Pfizer | Xeljanz | $19 | 1 payment
|
2019: $800
| AbbVie | Humira | $312 | 35 payments
|
| Janssen Biotech | Stelara | $165 | 13 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $116 | 7 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $86 | 4 payments
|
| Pfizer | Xeljanz | $35 | 2 payments
|
| Aries Pharmaceuticals | Eleview | $20 | 1 payment
|
| Vivus | Pancreaze | $20 | 1 payment
|
| Allergan | Linzess | $17 | 1 payment
|
| Merck Sharp & Dohme | Renflexis | $16 | 1 payment
|
| Ironwood Pharmaceuticals | Linzess | $14 | 1 payment
|
Checkups this office reported
2 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 100.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Patients can see their records onlinePatients who were given electronic access to their health information | 81%That's most of the people this applied to. | 133 |
| Prescriptions sent electronicallyPrescriptions sent to the pharmacy by computer instead of paper | 99%That's most of the people this applied to. | 203 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Agreed to federal review of their records system
- Chronic Care and Preventative Care Management for Empaneled Patients
- Did a security review of patient data
- High Priority Practices Guide of the Safety Assurance Factors for EHR Resilience (SAFER) Guides
- Implementation of formal quality improvement methods, practice changes, or other practice improvement processes
- Implementation of medication management practice improvements
- ONC-ACB Surveillance Attestation
- Reports cases to public health electronically
- Reports to a public-health or clinical registry
- Use of QCDR data for ongoing practice assessment and improvements
- Exempt from immunization registry reporting
- Exempt from query of the prescription drug monitoring program (pdmp)
- Exempt from support electronic referral loops by receiving and reconciling health information
- Exempt from support electronic referral loops by sending health information
Professional record
- NPI
- 1194055640
- Licence
- CA A109953California A109953: Current · expires 2027-04-30
- Trained
- Chicago College of Medicine and Surgery, 2008 · 18 years ago
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RG0100X (207RG0100X); Internal medicine (207R00000X); Federal specialty code 207RI0008X (207RI0008X)
- Mailing address
- 1809 Verdugo Blvd Ste 205, Glendale, CA, 91208
- NPI first listed
- 2010-01-06
- NPI last updated
- 2021-01-18
- NPI record certified
- 2021-01-18
This is when the NPI record was last certified, not a medical board exam.